

Lymphoma Research Foundation

Financial Statements
Year Ended June 30, 2024

The report accompanying these financial statements was issued by BDO USA, P.C., a Virginia professional corporation, and the U.S. member of BDO International Limited, a UK company limited by guarantee.



Lymphoma Research Foundation

Financial Statements
Year Ended June 30, 2024

Lymphoma Research Foundation

Contents

Independent Auditor's Report	3-4
Financial Statements	
Statement of Financial Position as of June 30, 2024	6
Statement of Activities for the Year Ended June 30, 2024	7
Statement of Functional Expenses for the Year Ended June 30, 2024	8
Statement of Cash Flows for the Year Ended June 30, 2024	9
Notes to Financial Statements	10-21



Independent Auditor's Report

The Board of Directors
Lymphoma Research Foundation
New York, New York

Opinion

We have audited the financial statements of Lymphoma Research Foundation, which comprise the statements of financial position as of June 30, 2024, the related statement of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Lymphoma Research Foundation as of June 30, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Lymphoma Research Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Lymphoma Research Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Lymphoma Research Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Lymphoma Research Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited Lymphoma Research Foundation's June 30, 2023 consolidated financial statements, and our report dated April 1, 2024 expressed an unmodified opinion on those audited consolidated financial statements. In our opinion, the summarized comparative information presented herein for the year ended June 30, 2023 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

BDO USA, P.C.

December 19, 2024

Financial Statements

Lymphoma Research Foundation

Statement of Financial Position (with comparative totals for 2023)

<i>June 30,</i>	2024	2023
Assets		
Current Assets		
Cash and cash equivalents (Note 2)	\$ 5,283,497	\$ 12,237,893
Investments, at fair value (Notes 2 and 4)	34,552,283	23,767,395
Contributions and grants receivable, current portion, (Notes 2 and 3)	1,451,760	2,265,890
Prepaid expenses and other assets	365,437	276,911
Total Current Assets	41,652,977	38,548,089
Contributions and Grants Receivable , net of current portion and discount (Notes 2 and 5)	-	957,029
Fixed Assets, Net (Notes 2 and 6)	33,483	59,990
Right-of-Use Asset , operating lease (Notes 2 and 9)	1,147,579	1,496,697
Total Assets	\$ 42,834,039	\$ 41,061,805
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$ 330,643	\$ 186,191
Accrued salaries and vacation	389,469	303,890
Refundable advances (Note 2)	191,090	125,000
Research and patient aid grants payable, current (Note 7)	1,479,980	525,000
Operating lease liability, current portion (Notes 2 and 9)	374,825	363,761
Total Current Liabilities	2,766,007	1,503,842
Research and Patient Aid Grants Payable , less current portion and discount (Note 7)	6,489,280	8,026,640
Operating Lease Liability , net of current portion (Notes 2 and 9)	817,905	1,192,730
Total Liabilities	10,073,192	10,723,212
Commitments (Notes 2, 3, 5, 7, 8, 9, and 10)		
Net Assets		
Without donor restrictions	7,993,253	4,979,089
With donor restrictions (Note 10)	24,767,594	25,359,504
Total Net Assets	32,760,847	30,338,593
Total Liabilities and Net Assets	\$ 42,834,039	\$ 41,061,805

See accompanying notes to financial statements.

Lymphoma Research Foundation

Statement of Activities (with comparative totals for 2023)

Year ended December 31,

	Without Donor Restrictions	With Donor Restrictions	Total	
			2024	2023
Revenues and Support				
Contributions and grants	\$ 2,580,865	\$ 8,175,077	\$ 10,755,942	\$ 14,080,819
Contributions of nonfinancial assets	1,266,975	-	1,266,975	768,600
Special events, net of direct expenses of \$354,933 for 2024	2,186,116	-	2,186,116	2,163,923
Investment income, net of fees	2,682,481	-	2,682,481	484,011
Other income	227,520	-	227,520	9,384
Net assets released from restrictions (Note 10)	8,766,987	(8,766,987)	-	-
Total Revenues and Support	17,710,944	(591,910)	17,119,034	17,506,737
Expenses				
Program services:				
Education programs and support services	4,131,044	-	4,131,044	3,060,144
Research programs	5,741,723	-	5,741,723	6,962,525
Community outreach and advocacy	1,096,456	-	1,096,456	1,157,029
Total Program Services	10,969,223	-	10,969,223	11,179,698
Supporting services:				
Administration	1,871,046	-	1,871,046	1,376,459
Fundraising	1,856,511	-	1,856,511	2,168,038
Total Supporting Services	3,727,557	-	3,727,557	3,544,497
Total Expenses	14,696,780	-	14,696,780	14,724,195
Change in Net Assets	3,014,164	(591,910)	2,422,254	2,782,542
Net Assets, beginning of year	4,979,089	25,359,504	30,338,593	27,556,051
Net Assets, end of year	\$ 7,993,253	\$ 24,767,594	\$ 32,760,847	\$ 30,338,593

See accompanying notes to financial statements.

Lymphoma Research Foundation

**Statement of Functional Expenses
(with comparative totals for 2023)**

Year ended June 30,

	Program Services				Supporting Services			Total	
	Education Programs and Support Services	Research Programs	Community Outreach and Advocacy	Total Program Services	Administration	Fundraising	Total Supporting Services	2024	2023
Salaries and Related Expenses									
Salaries	\$ 1,291,554	\$ 441,529	\$ 184,730	\$ 1,917,813	\$ 194,185	\$ 1,160,559	\$ 1,354,744	\$ 3,272,557	\$ 3,130,118
Payroll, taxes, and employee benefits	276,093	92,721	81,120	449,934	72,540	222,397	294,937	744,871	913,472
Total Salaries and Related Expenses	1,567,647	534,250	265,850	2,367,747	266,725	1,382,956	1,649,681	4,017,428	4,043,590
Other Expenses									
Research and patient aid grants	44,100	3,239,004	-	3,283,104	-	-	-	3,283,104	4,949,516
Conferences and events	986,971	363,968	-	1,350,939	67,543	69,695	137,238	1,488,177	1,265,366
Dues and subscriptions	41,328	37,329	45,869	124,526	234,441	25,743	260,184	384,710	303,341
Insurance	24,809	9,320	4,453	38,582	25,031	-	25,031	63,613	37,498
Licenses and permits	36	-	-	36	10,093	3,378	13,471	13,507	13,786
Marketing and promotion	305,639	10,190	221,945	537,774	9,657	34,989	44,646	582,420	639,431
Processing fees and other	70	-	-	70	70,527	-	70,527	70,597	201,873
Office equipment	13,037	3,677	2,340	19,054	14,374	11,204	25,578	44,632	49,057
Office supplies	108,769	5,000	115	113,884	35,601	19,576	55,177	169,061	65,015
Postage and shipping	199,655	5,640	1,210	206,505	36,131	101,852	137,983	344,488	120,527
Printing and publications	6,271	1,200	-	7,471	-	-	-	7,471	244,453
Professional fees	451,605	1,339,124	514,724	2,305,453	921,703	87,202	1,008,905	3,314,358	1,963,723
Rent and utilities	174,706	49,206	34,375	258,287	101,941	74,344	176,285	434,572	407,238
Repairs and maintenance	-	-	-	-	4,786	-	4,786	4,786	2,895
Telecommunications	12,147	183	181	12,511	51,372	383	51,755	64,266	59,329
Travel	183,916	140,716	3,539	328,171	9,723	45,189	54,912	383,083	314,292
Depreciation and amortization	10,338	2,916	1,855	15,109	11,398	-	11,398	26,507	43,265
Total Expenses	\$ 4,131,044	\$ 5,741,723	\$ 1,096,456	\$ 10,969,223	\$ 1,871,046	\$ 1,856,511	\$ 3,727,557	\$ 14,696,780	\$ 14,724,195

See accompanying notes to financial statements.

Lymphoma Research Foundation

Statement of Cash Flows (with comparative totals for 2023)

<i>Year ended June 30,</i>	2024	2023
Cash Flows from Operating Activities		
Change in net assets	\$ 2,422,254	\$ 2,782,542
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	26,507	43,265
Realized loss (gain) on sale of investments	87,993	(45)
Unrealized gain on investments	(1,926,321)	(171,181)
Change in discount on contributions and grants receivable	(42,971)	(55,524)
Change in discount on research and patient aid grants payable	60,693	(223,312)
Non-cash lease expenses	349,118	412,818
Decrease (increase) in:		
Contributions receivable	1,814,130	(277,169)
Prepaid expenses and other assets	(88,526)	8,436
Increase (decrease) in:		
Accounts payable and accrued expenses	144,452	(612,368)
Accrued payroll, vacation, and related taxes payable	85,579	49,585
Refundable advances	66,090	(70,373)
Research and patient aid grants payable	(643,073)	2,033,062
Principal reduction in operating lease liabilities	(363,761)	(353,024)
Net Cash Provided by Operating Activities	1,992,164	3,566,712
Cash Flows from Investing Activities		
Proceeds from sale of investments	116,035,746	7,803,363
Purchase of investments	(124,982,306)	(8,239,914)
Purchase of fixed assets	-	(3,531)
Net Cash Used in Investing Activities	(8,946,560)	(440,082)
Net (Decrease) Increase in Cash and Cash Equivalents	(6,954,396)	3,126,630
Cash and Cash Equivalents, beginning of year	12,237,893	9,111,263
Cash and Cash Equivalents, end of year	\$ 5,283,497	\$ 12,237,893

See accompanying notes to financial statements.

Lymphoma Research Foundation

Notes to Financial Statements

1. Nature of Organization

The Lymphoma Research Foundation (the Foundation) is a nonprofit corporation, which is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) and similar provisions at the state and local level. The Foundation is the nation's largest nonprofit organization devoted to only funding innovative lymphoma research and providing patients and their families and healthcare professionals with up-to-date education about this type of cancer. The Foundation's mission is to eradicate lymphoma and serve those touched by this disease. The Foundation's primary sources of income are contributions and grants.

To help ensure that the amounts the Foundation raises are directed toward cutting-edge lymphoma-related research, decisions of what research will be funded are made by the deliberations of the Foundation's Scientific Advisory Board (SAB). The SAB comprises a volunteer group of scientists and clinicians distinguished in the fields of lymphoma research and treatment. They make their judgments on applications for funding based on the scientific and innovative merits of the projects proposed, the demonstrated ability of the researcher and sponsor, and the suitability of the institution. The members of the SAB review the applications independently and then meet to discuss the proposals at periodic meetings scheduled throughout the year.

In addition to evaluating grant applications, the SAB counsels the Foundation's Board of Directors and staff on the direction of its overall strategic scientific agenda in order to remain current with the pace and direction of the rapidly evolving area of blood cancer research.

The Board of Directors studies the recommendations of the SAB. Its aim is to approve those recommended grant applications and projects which seem most likely to have an impact on lymphoma-related research and treatments, and therefore, most likely to help the Foundation achieve its overall goals. The Foundation funds research projects submitted by individuals associated with accredited academic institutions, Joint Commission on Accreditation of Healthcare Organizations, accredited research hospitals, and other research organizations that have strong national and international reputations.

The Foundation is also dedicated to serving those touched by lymphoma. To accomplish this, the Foundation provides national, regional, and local educational conferences and symposiums; advocacy programs; online webcast educational programming; telephone educational workshops; and educational publications. The Foundation's educational programs and publications provide lymphoma patients and their loved ones with current and comprehensive information about the disease, its treatments, promising research in lymphoma, and how to better manage the psycho/social issues associated with living with lymphoma. The Foundation also offers a Lymphoma Helpline and Clinical Trials Information Service, a nationwide peer support program, and financial assistance to lymphoma patients receiving treatment.

During fiscal year 2017, the Foundation established a subsidiary, LRF Research, Inc., as part of a strategic relationship with the Clarus Cancer Fund, an investment fund of Clarus Ventures. There was no activity at LRF Research, Inc. and was dissolved in fiscal year 2023.

Lymphoma Research Foundation

Notes to Financial Statements

2. Summary of Significant Accounting Policies

Basis of Presentation

The Foundation's financial statements have been prepared on the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America (GAAP). In the statement of financial position, assets and liabilities are presented in order of liquidity or conversion to cash and their maturity resulting in the use of cash, respectively.

Financial Statement Presentation

The of the Foundation's net assets and its support, revenue, and expenses is based on the existence or absence of donor-imposed restrictions. It requires that the amounts for each of the two classes of net assets—net assets without donor restrictions and net assets with donor restrictions—be displayed in the statement of financial position and that the amounts of change in each of those classes of net assets be displayed in the statement of activities.

These classes are defined as follows:

Net Assets Without Donor Restrictions - This class consists of the part of net assets that are not subject to donor-imposed stipulations and are, therefore, available for the general operations of the Foundation.

Net Assets with Donor Restrictions - This class consists of net assets resulting from contributions and other inflows of assets whose use by the Foundation is limited by donor-imposed stipulations that either expire by the passage of time or can be fulfilled and removed by the actions of the Foundation, pursuant to those stipulations. When such stipulations end or are fulfilled, such net assets are reclassified to net assets without donor restrictions and reported as net assets released from restrictions in the statements of activities.

Net assets with donor restrictions also include net assets resulting from contributions whereby the principal has been stipulated by the donor to be held and invested in perpetuity and the income used in accordance with the donor's stipulations, if any. At June 30, 2024, the Foundation had no net assets with donor restrictions that are perpetual in nature.

Cash and Cash Equivalents

The Foundation considers all highly liquid investments with an original maturity of 90 days or less when acquired to be cash equivalents, except for those cash equivalents held for short-term investment that are maintained in the Foundation's investment portfolio.

The Foundation maintains its cash in bank deposit accounts, which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Foundation does not believe it is exposed to any significant risk from cash and cash equivalents.

Fair Value Measurements

The Foundation follows Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, which establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most

Lymphoma Research Foundation

Notes to Financial Statements

observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Foundation. Unobservable inputs are inputs that reflect the Foundation's assumptions about the factors market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs, as follows:

Level 1 - Valuations are based on quoted prices in active markets for identical assets or liabilities. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 - Valuations are based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 2 inputs include: (i) quoted prices for similar assets or liabilities in active markets, (ii) quoted prices for identical assets or liabilities traded in non-active markets (i.e., dealer or broker markets), and (iii) inputs other than quoted prices that are observable, or inputs derived from or corroborated by market data.

Level 3 - Valuations are based on inputs that are unobservable and significant to the overall fair value measurement.

Investment Income

Investment income is recognized when earned and consists of interest, dividends, and realized and unrealized gains and losses, less direct external investment expenses. Dividends are recorded at the ex-dividend date. Purchases and sales are recorded on a trade-date basis.

Income earned from investments restricted in perpetuity, including realized and unrealized gains and losses, are recorded as net assets with donor restrictions and then released to net assets without donor restrictions through appropriations made in accordance with the Foundation's spending policy.

Contributions

Contributions received, including unconditional promises to give are reported at their net realizable values. Gifts of cash and other assets are reported as support with donor restrictions if they are received with donor stipulations that limit their use or if they are intended to support activities in future periods. Contributions with donor-imposed restrictions that limit their use are reported in net assets with donor restrictions until the donor restrictions expire—that is, when a time restriction ends or purpose restriction is fulfilled. Upon the expiration of donor stipulations, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the accompanying statements of activities as net assets released from restrictions. Contributions are nonexchange transactions in which no commensurate value is exchanged. Therefore, contributions fall under the purview of ASC Topic 958, *Not-for-Profit Entities*.

A contribution, gift, or grant is conditional if an agreement includes a barrier that must be overcome and either a right of return of assets transferred or a right or release of a promisor's obligation to transfer assets. The presence of both a barrier and a right of return or right of release indicates that a recipient's promises to give are not recognized until they become unconditional—that is, when the barriers in the agreement are overcome. There are no outstanding conditional grants as of June 30, 2024.

Lymphoma Research Foundation

Notes to Financial Statements

Management determines the allowance for doubtful contributions receivable by regularly evaluating individual contributions receivable and considering prior history of donors and proven collectability of past donations. Contributions receivable are written off when deemed uncollectible.

Special Events

The Foundation applies Financial Accounting Standards Board (FASB) ASC 606, *Revenue from Contracts with Customers*, to exchange transactions when applicable. Most of the Foundation's revenue for the year ended June 30, 2024 were from non-exchange transaction revenue sources including contributions, contributed non-financial assets and investment income.

ASC 606 applies to the portion of the Foundation's special events income that is determined to be an exchange transaction. The Foundation conducts special events in which a portion of the gross proceeds paid by the participant represents payment for the direct cost of the benefits received by the participant at the event. Unless a verifiable, objective means exists to demonstrate otherwise, the fair value of meals and entertainment provided at special events is measured at the actual cost to the Foundation. The direct costs of the special events which ultimately benefit the donor rather than the Foundation are recorded as exchange transaction revenue and exchange transaction expense. All proceeds received in excess of the direct costs are recorded as special events income in the accompanying statements of activities.

For the year ended June 30, 2024, the Foundation reported special event revenue of \$1,526,543 and direct expenses of \$354,933 which is recognized as an exchange transaction.

Contributed Nonfinancial Assets

Amounts are reported in the financial statements for voluntary donations of services if those services create or enhance non-financial assets or require specialized skills provided by individuals possessing those skills and which would typically be purchased if not provided by donation. During the year ended June 30, 2024, the Foundation received \$1,266,975 in contributions in kind that are reported as contributions and expenses in the accompanying statements of activities and functional expenses. The amount is associated with the recognition of time spent by SAB members to carry out the requirements of its research program, as well as support the Foundation's professional and patient education programs. Without the volunteer support these physicians provide the Foundation, the organization would be required to compensate physicians to perform these services.

A substantial number of other volunteers have donated significant amounts of their time in supporting the Foundation's activities. No amounts have been reflected in the accompanying financial statements for these donated services since they do not meet the criteria for recognition.

The following summarizes the Foundation's contributed nonfinancial assets for the year ended June 30, 2024:

	Revenue Recognized	Donor Restrictions	Valuation Techniques and Inputs
Professional services	\$ 1,266,975	No associated donor restrictions	Valued based on prevailing rates of professional time

Lymphoma Research Foundation

Notes to Financial Statements

Fixed Assets

Fixed assets are stated at cost or at their fair market values at the time of their donation. The Foundation capitalizes additions that are purchased if the estimated useful life is greater than one year. Depreciation is computed over the estimated useful lives of the assets by the straight-line method for financial reporting, as follows:

	Estimated Useful Lives (Years)
Furniture and office equipment	2-5
Computer equipment and software	2
Leasehold improvements	Lesser of lease term or useful life

Impairment of Long-Lived Assets

The Foundation follows the provisions of ASC 360-10-35, *Accounting for the Impairment or Disposal of Long-Lived Assets*, which requires the Foundation to review long-lived assets, including both fixed and intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future cash flows from the use of the asset are less than the carrying amount of that asset. For the year ended June 30, 2024, there were no impairments recorded in the financial statements.

Grant Expense

Grant expense is recognized in the period the grant is approved by the Foundation's Board of Directors, provided the grant is not subject to significant future conditions.

Refundable Advances

Amounts received by the Foundation for certain special events are reflected as refundable advances until the event occurs. The majority of these amounts are characterized by the Foundation as an exchange transaction.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis. The statements of functional expenses present expenses by function and natural classification. Where practicable, expenses are directly classified to specific program or supporting service categories. Costs that are not specifically identifiable within functional categories are classified using an allocation methodology based on an estimate of time and effort.

Income Taxes

The Foundation follows GAAP, which requires accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and measurement. GAAP provides that the tax effects from an uncertain tax position can only be recognized in the financial statements if the position is "more likely than not" to be sustained if the position were to be challenged by a taxing authority. The assessment of the tax position is based

Lymphoma Research Foundation

Notes to Financial Statements

solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged.

The Foundation is incorporated in the state of California and is exempt from federal income tax under IRC Section 501(c)(3), though it is subject to tax on income unrelated to its exempt purpose, unless that income is otherwise excluded by the IRC. The Organization has no unrelated income associated with its exempt purpose. The Foundation has processes presently in place to ensure the maintenance of its tax-exempt status, to identify and report unrelated income, to determine its filing and tax obligations in jurisdictions for which nexus was established, and to identify and evaluate other matters that may be considered tax positions. The Foundation has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements. As of December 31, 2023, the Foundation was not subject to an examination by a taxing authority.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the financial statements and revenue and expenses recognized during the reporting period. Estimates made in the preparation of the financial statements include the net realizable value of contributions and grants receivable, the valuation of contributed services, and functional expense allocations. Actual results could differ from those estimates.

Comparative Financial Information

The financial statements include certain prior year summarized comparative information. With respect to the statement of activities, the prior-year information is presented in total, not by net asset class. With respect to the statement of functional expenses, the prior-year expenses are presented by expense classification in total rather than functional category. Such information does not include sufficient detail to constitute a presentation in conformity with GAAP. Accordingly, such information should be read in conjunction with the Foundation's consolidated financial statements for the year ended June 30, 2023, from which the summarized information was derived.

Accounting Pronouncement Recently Adopted

Financial Instruments - Credit Losses

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments - Credit Losses (Topic 326)*. The ASU introduces a new credit loss methodology, *Current Expected Credit Losses (CECL)*, which requires earlier recognition of credit losses, while also providing additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU.

The CECL methodology utilizes a lifetime "expected credit loss" measurement objective for the recognition of credit losses for loans, held-to-maturity securities, and other receivables at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. The methodology replaces the multiple existing impairment methods in current GAAP, which require that a loss be incurred before it is recognized. For available-for-sale securities where fair value is less than cost, credit-related impairment, if any, is recognized through an allowance for credit losses and adjusted each period for changes in credit risk.

Lymphoma Research Foundation

Notes to Financial Statements

On July 1, 2023, the Foundation adopted the guidance prospectively. There was no cumulative adjustment recorded. At adoption and at June 30, 2024, the Foundation did not recognize an incremental allowance for credit losses related to its accounts receivable balances.

3. Contributions and Grants Receivable

Contributions and grants receivable are scheduled to be collected as follows:

June 30, 2024

Amount due in one year or less	\$ 1,451,760
Contributions and Grants Receivable	\$ 1,451,760

Contributions and grants receivable due after one year are discounted to net present value using risk adjusted interest rates in effect on the date of the gifts.

4. Investments, at Fair Value

The Foundation's assets recorded at fair value have been categorized based upon a fair value hierarchy, in accordance with ASC 820. See Note 2 for a discussion of the Foundation's policies regarding this hierarchy.

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used as of June 30, 2024.

The Foundation's Level 1 holdings within the hierarchy used in measuring fair value consist of money market funds, mutual funds, and equity securities, which are carried at their market value, which is determined by quoted market prices. Each of the above investments can be liquidated daily.

The Foundation has investments in fixed-income securities, which include government and agency securities, corporate bonds, foreign bonds, and mutual funds. The investment managers priced these investments using nationally recognized pricing services. Since fixed-income securities other than U.S. Treasury securities may not trade on a daily basis, the pricing services prepare estimates of fair value measurements for these securities using their proprietary pricing applications, which include available relevant market information, benchmark curves, benchmarking of similar securities, sector grouping, and matrix pricing. These investments are classified as Level 2.

The remainder of this page was intentionally left blank.

Lymphoma Research Foundation

Notes to Financial Statements

The following tables present the level within the fair value hierarchy at which the Foundation's assets are measured on a recurring basis:

June 30, 2024

	Level 1	Level 2	Total
Investments			
Money market funds	\$ 1,200,784	\$ -	\$ 1,200,784
Fixed income	1,903,513	4,135,726	6,039,239
Equities	10,692,466	-	10,692,466
Mutual funds	16,619,794	-	16,619,794
Total Investments, at fair value	\$ 30,416,557	\$ 4,135,726	\$ 34,552,283

Investment income, net of fees consists of the following:

Year ended June 30, 2024

Interest and dividends, net of fees	\$ 844,153
Realized and unrealized gain on investments	1,838,328
	\$ 2,682,481

5. Liquidity and Availability of Resources

The Foundation's financial assets available within one year of the balance sheet date for general expenditures, such as program expenses, grants, and other operating expenses, are as follows:

June 30, 2024

Net Financial Assets	
Cash and cash equivalents	\$ 5,283,497
Contributions and grants receivable	1,451,760
Investments, at fair value	34,552,283
Total Financial Assets, end of year	41,287,540
Less: those unavailable for general expenditure within one year, due to:	
Donor-imposed program restrictions	(24,767,594)
Total Financial Assets Available Within One Year	\$ 16,519,946

The Foundation's Board of Directors approves an annual operating budget and cash availability sufficient to meet projected cash needs. The Foundation maintains cash and highly liquid securities sufficient to meet anticipated cash needs for operations, capital commitments, and new investments over a 12-month rolling period.

Lymphoma Research Foundation

Notes to Financial Statements

6. Fixed Assets, Net

Major classes of fixed assets, net, consist of the following:

June 30, 2024

Furniture and office equipment	\$	20,333
Computer equipment and software		61,685
Leasehold improvements		113,640
Property and Equipment		195,658
Less: accumulated depreciation and amortization		(162,175)
Property and Equipment, Net	\$	33,483

Depreciation and amortization expense amounted to \$26,507 for the year ended June 30, 2024.

7. Research and Patient Aid Grants

Research grant expense is recorded when the grant is approved by the Foundation and the grantee is notified and has executed the award. Research grants are generally awarded for a two to three-year period, with payments made quarterly.

The Foundation offers a financial assistance program for people currently undergoing treatment for lymphoma. Patient aid grants assist with quality-of-life expenses.

The following table provides grant activity for fiscal years 2024 and 2023:

Year ended June 30, 2024

Research and Patient Aid Grants Payable , beginning of year	\$	8,551,640
Grants awarded, net of cancellations		3,600,609
Grant payments		(3,898,984)
Discount on research and patient aid grants payable		(284,005)
Research and Patient Aid Grants Payable , end of year	\$	7,969,260

Research and patient aid grants payable are scheduled to be paid as follows:

June 30, 2024

Amount payable in one year or less	\$	1,479,980
Amount payable in more than one year		6,773,285
Less: discount on research and patient aid grants payable		(284,005)
	\$	7,969,260

In 2024, the Foundation authorized research grant awards of \$3,690,000, which included the re-awarded 2023 amount, for which grant agreements were provided to recipients. Of this amount, approximately \$120,000 of the grant agreements were not executed by the prospective grantee or the grantee did not utilize all of the funds. The grant awards not executed will be awarded in fiscal

Lymphoma Research Foundation

Notes to Financial Statements

year 2025 to other grantees. Research and patient aid grants payable due after one year are discounted to net present value using risk-adjusted interest rates in effect on the date of the award.

8. Employee Benefit Plan

The Foundation maintains a retirement plan pursuant to Internal Revenue Code Section 403(b) for its employees. Employees are eligible to participate immediately. Under the terms of the plan, employees are entitled to defer a portion of their annual compensation, within limitations established by the Internal Revenue Code. During 2006, the Foundation started a matching program whereby it contributes an amount equal to 5% of annual compensation for eligible employees provided that the employees contribute at least 3% to the plan. Retirement expense under the plan amounted to \$116,075 for the year ended June 30, 2024.

9. Leases

The Foundation has adopted the provisions of ASC 842, *Leases*. For leases with initial terms of greater than one year (or initially, greater than one year remaining under the lease at the date of the adoption of ASC 842), the Foundation records the related right-of-use (ROU) assets and liabilities at the present value of the remaining lease payments to be paid over the life of the related lease. Lease payments related to periods subject to renewal options are excluded from the amounts used to determine the present value of the remaining lease payments unless the Foundation is reasonably certain to exercise the option to extend the lease. The Foundation leases its office space under an operating lease in New York City through August 31, 2027. This lease is deemed to be an operating lease based on the underlying terms of the agreement and the criteria included in ASC 842. The lease requires monthly payments of principal and interest at a rate of 3% per annum. The present value of the lease payments is calculated by utilizing the discount rate stated in the lease, when readily determinable. For leases for which a discount rate is not readily available, the Foundation has elected to use the incremental borrowing rate based on the information available at the lease inception date. The Foundation has made an accounting policy election not to separate lease components from non-lease components in contracts when determining its lease payments for all of its asset classes, as permitted by ASC 842. As such, the Foundation accounts for the applicable non-lease components together with the related lease components when determining the ROU assets and liabilities. The Foundation has made an accounting policy election not to record leases with an initial term of less than one year as ROU assets and liabilities in the statement of financial position.

The following tables summarize information related to the lease assets and liabilities:

Year ended June 30, 2024

Lease Costs

Operating lease cost:

Amortization of ROU assets	\$	349,118
Interest on lease liabilities		40,709

Total Lease Cost	\$	389,827
-------------------------	-----------	----------------

June 30, 2024

ROU Assets and Liabilities

Operating lease ROU asset, net of amortization	\$	1,147,579
Operating lease liability		1,192,730

Lymphoma Research Foundation

Notes to Financial Statements

Year ended June 30, 2024

Other Information

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases	\$	404,470
Weighted-average remaining lease term - operating leases		3.08 years
Weighted-average discount rate - operating leases		3%

For operating leases, ROU assets are recorded in operating lease ROU assets, net, and lease liabilities are recorded in operating lease liabilities in the accompanying statement of financial position.

The following is a schedule of future minimum lease payments, including interest, under the term of the leases, together with the present value of the net minimum lease payments, as of June 30, 2024:

Year ending June 30,

2025	\$	404,470
2026		404,470
2027		404,470
2028		33,706
Total Minimum Lease Payments		1,247,116
Less: amounts representing interest		54,386
Present Value of Net Minimum Lease Payments		1,192,730
Less: current portion		374,825
	\$	817,905

10. Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following:

<i>June 30,</i>		2024
Research programs	\$	10,995,332
Education programs and support services		13,451,242
Patient aid		321,020
	\$	24,767,594

Lymphoma Research Foundation

Notes to Financial Statements

Net assets were released from restrictions during the years ended June 30, 2024 and 2023 by incurring expenses or the passage of time, thus satisfying the restricted purposes as follows:

<i>Year ended June 30,</i>		<i>2024</i>
Research programs	\$	4,327,250
Education programs and support services		4,395,637
Patient aid		44,100
	\$	8,766,987

11. Subsequent Events

In connection with the preparation of the financial statements, the Foundation evaluated subsequent events after the balance sheet date of June 30, 2024 through December 19, 2024, which was the date the financial statements were available to be issued, and determined that there were no matters that are required to be disclosed.